MedTech Industry Dynamics
MedTech Industry Dynamics
The UK government has launched the Dementia Challenge, backed by up to £80 million, to accelerate adoption of innovative diagnostic technologies in the NHS, with the goal of diagnosing 92% of people within 18 weeks of referral compared with around 60% today.
Read MoreC2N Diagnostics has partnered with Cambridge Cognition and The Alzheimer’s Trust on World Alzheimer’s Day to create an integrated, scalable diagnostic pathway in the UK, combining the PrecivityAD2 blood test, CANTAB Pathway digital cognitive assessments, and national phlebotomy and MRI infrastructure.
Read MoreRoche has received FDA clearance for its Elecsys pTau217 blood test, the first and only FDA-cleared single-biomarker test supporting both rule-in and rule-out assessment of amyloid pathology. Quest Diagnostics and Labcorp will offer the test to clinicians nationwide.
Read MoreC2N Diagnostics has received FDA clearance for its PrecivityAD2 blood test, the first Alzheimer’s diagnostic aid cleared for use in symptomatic adults aged 40 and older, delivering high diagnostic performance to help clinicians rule in or rule out clinical Alzheimer’s disease.
Read MoreEmpatica has received FDA 510(k) clearance for its Health Monitoring Platform for Parkinson’s, enabling continuous symptom monitoring through clinical-grade wearables to support personalized care and clinical research.
Read MoreBeckman Coulter Diagnostics has received CE Mark under IVDR for its Access p-Tau217 blood test to support clinical evaluation of amyloid pathology in cognitive decline, while also launching a high-specificity brain-derived pTau217 research assay for neurodegenerative research.
Read MoreTOBY has received FDA Breakthrough Device Designation for its urine-based Alzheimer’s disease diagnostic test, which uses urinary volatile organic compound patterns analyzed through mass spectroscopy and machine learning to aid in diagnosis through a simple, non-invasive sample.
Read MoreNeuroVision Imaging has acquired Durin Life Sciences, combining blood-based biomarker tests, retinal imaging technology, and a telehealth platform to support earlier detection and longitudinal care for Alzheimer’s, Parkinson’s, and other neurological disorders.
Read MoreSiemens Healthineers has introduced new blood-based biomarker assays for brain health research, aiming to support studies on neurological diseases and reduce reliance on invasive diagnostic methods.
Read MoreCognito Therapeutics has secured $105 million in oversubscribed Series C financing to support clinical development and regulatory plans for Spectris, an investigational at-home neurotechnology therapy for Alzheimer’s disease.
Read More
